gretel
21 Nov 2016
Re: H1 Results If Allergy and Autoimmune were sold then the existing business would be better off than it is now.Per the Business Segment Note to today's H1 results, Allergy and Autoimmune actually made a £40k adjusted loss in H1.Whereas Food Intolerance made a £1,65m profit, representing the entirety of the H1 profit before central costs.Post-sale or transfer into JV, ODX' core business would therefore be both more profitable and fully funded for growth globally and in CD4 in particular.
Carefully Does It
21 Nov 2016
Re: Results at Whatever is left over would need a growth path capable of making up for the reduced business size. Cash from the allergen side would certainly help. How much of the current p/e is down to the allergen side and how much to new CD4 etc?
Ambiorix1
21 Nov 2016
Re: Results at Then the question would be : what is left ? Could it then be merged with...let's say Genedrive ?Ambiorix.
gretel
21 Nov 2016
Re: Results at Apparently Allersys development spend as of the last final report stood at £5.5m, so it's likely that any takeout price would actually be nearer £12m or more.Conveniently, IDH have £26m of cash.
gretel
21 Nov 2016
Results at "higher end" of expectations Great to see ODX able to confirm already that PBT for the year is "expected to be at the higher end of market expectation".And that the malaria and pregnancy tests will be available for sale in Q4.And Allersys might be sold, as well as the entire Allergy business. Does this include the Autoimmune operation as well?With say £3.5m sales in the year it might be worth say 1.5 times revenues, plus a decent amount for the now commercialised Allersys too, so say £8m-£9m? That's a complete stab in the dark, so feel free to disagree completely!
Ambiorix1
21 Nov 2016
and this is Monday.... ...We have recently been approached by our Allersys licensor (Immunodiagnostic Systems Holdings plc "IDS"
with a view to changing the nature of the commercial relationship with the Company. This could extend to the acquisition of all or part of our Allergy Business...i.e. partial takeover ???. Ambiorix
gretel
18 Nov 2016
H1 results out on Monday We know from the update that the results will be good, so we may well see a move upwards in the share price in reaction.Hopefully there will be more news on CD4 and Allersys, though there was a pretty full update on 17th October, so I'm not sure there'll be much more to say since then.
gretel
01 Nov 2016
New report from Hardman Research [link] forecast 1.14p EPS this year and 1.25p EPS next year. With the various "blue sky" opportunities now at or approaching commercialisation they're almost in the current price for free.
gretel
17 Oct 2016
Finncap retain 28p target [link]
gretel
17 Oct 2016
Excellent update today The core business continues to grow steadily, with Food Intolerance - the dominant sector - really gaining traction."Strong growth" in North America is particularly encouraging.Meanwhile, all the "blue sky" stuff is progressing well and is starting to become a commercial reality as regards Allersys with a first purchase order, plus CD4, Pune etc showing good progress.There's big potential upside here imho over time.
gretel
12 Oct 2016
Huge increase in allergies Big media coverage everywhere today about the huge increase in allergic reactions and anaphylactic shocks:[link] amazing statistic here - which must be good news for ODX:"Data about how many people in the UK suffer from an allergy is not conclusive but the charity Allergy UK claims that up to 50% of children are now diagnosed with an allergic condition"
The Specialist
02 Aug 2016
Re: RNS today re £1.8m grant win! This is indeed a huge grant when compared to some NGOs recent grants but more importantly highlights external confidence in the company and its product line.
The Specialist
02 Aug 2016
Re: RNS today re £1.8m grant win! Great news which allows them to develop their Allergens business in an accelerated fashion and once CD4 passes field tests done funds could be used to accelerate productions. Brilliant development all round.
gretel
02 Aug 2016
RNS today re £1.8m grant win! Wow - RNS today for ODX's receipt of a £1.8m grant towards Allersys 
))[link] (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has secured a Scottish Enterprise research and development grant of £1.8 million. The R&D grant represents a significant contribution towards the total R&D project costs to fund the planned expansion of the Company's Allersys® range of reagents for use in allergy in vitro diagnostics. The project funding will be used to accelerate a growth in menu from 41 allergens to 120 allergens over the next three years to cope with anticipated increasing demand as noted by the following references: etc"
gretel
21 Jul 2016
New article on ODX Nice article here written by Charles Breese, a successful investment manager for over 30 years:[link] "AIM listed Omega Diagnostics recently released its final results to March 2016 - its business is developing and marketing assays for the Allergy and Autoimmune, Food Intolerance, and Infectious Disease sectors. The architect of the company is David Evans, a leading UK developer of healthcare diagnostic companies - he played a key role in the development of DxS leading to its acquisition by Qiagen. I have followed (and become a shareholder in) Omega following its reversal into an AIM listed company in September 2006 - its sales were then only £2 million, but it had a distribution network covering over 100 countries, which meant that Omega could acquire businesses which were predominantly selling in their home countries and resource efficiently enable them to expand internationally. Since 2006, Omega has made several acquisitions. The results to March 2016 showed sales of £12.7 million and adjusted operating profit of £971,000, with Food Intolerance being the prime driver of organic growth with sales of £7.1 million and the sales of the other two divisions being split c.50/50. What makes the company interesting is that this profitable business has been undertaking two developments each of which has the potential to deliver transformational growth, namely: IDS/Allersys In 2010, the German allergy business, Allergopharma, was acquired from Merck - its sales were based entirely on manual assays. However, in order to significantly expand the business both within Germany and internationally, it was necessary for the assays to be able to be used on automated instruments. Accordingly, a contract was signed with AIM listed Immunodiagnostic Systems (IDS) for exclusive use of the IDS-iSYS automated instrument worldwide within the allergy market - the development of the initial menu of 41 allergen assays for use on the instrument has been technically challenging, but discussions are now at an advanced stage to achieve sales in 2016/17 via IDS and its marketing partners. Visitect CD4 In June 2012, Omega acquired exclusive access to two point-of-care tests (one for CD4 and the other for Syphilis) developed by the Burnet Institute in Australia - testing for the number of CD4 T-cells is a vital component for the management and care of people suffering from HIV and is required to determine when HIV patients should commence antiretroviral treatment - again the technical challenges encountered have been significant but considerable progress has been made, albeit that the commercialisation timetable is behind that for IDS/Allersys. The product has been developed so as to be economic for use in less developed countries, where there is a signicant HIV population.My holy grail of SMARTCO investing is to find profitable companies on reasonable valuations undertaking developments capable of transforming the business!"
